<DOC>
	<DOCNO>NCT01014442</DOCNO>
	<brief_summary>This open-label , single center study ass pharmacokinetics , efficacy safety mycophenolate mofetil lung allograft recipient . Participants split 2 group accord original disease : Group A ( cystic fibrosis ) Group B ( chronic obstructive pulmonary disease [ COPD ] , emphysema , idiopathic pulmonary fibrosis , alpha-1 antitrypsin deficiency [ A1AD ] ) . All participant receive mycophenolate mofetil orally , 1.5 gram ( g ) twice daily ( BID ) Day 2 30 post transplantation , 1 g BID Day 31 90 post transplantation . Anticipated time study treatment 90 day , target sample size 50-100 individual .</brief_summary>
	<brief_title>A Study Mycophenolate Mofetil ( CellCept ) Lung Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>primary single bilateral lung allograft original disease cystic fibrosis , COPD , emphysema , idiopathic pulmonary fibrosis A1AD lung allograft retransplantation multiple organ transplantation severe gastrointestinal disorder malignancy history malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>